Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: "Christoph Wanner" Clear advanced filters

  • Although renal dysfunction can have a profound effect on the pathogenesis of cardiovascular disease, current guidelines for the management of hyperlipidemia in patients with chronic kidney disease (CKD) were formulated in the absence of data on cardiovascular and cerebrovascular outcomes in this population. Considering the individual stages of CKD, authors from the University of Würzburg, Germany, analyze data from the 4D trial and other studies, and attempt to answer the question of when hyperlipidemia should (or should not) be treated in patients with CKD.

    • Vera Krane
    • Christoph Wanner
    Reviews
    Nature Clinical Practice Nephrology
    Volume: 2, P: 176-177

  • A new study by Chang et al. reports that coronary artery bypass grafting (CABG) may be preferable to percutaneous coronary intervention (PCI) for multivessel coronary revascularization in appropriately selected patients on maintenance dialysis.

    • Christoph Wanner
    • Kitty J. Jager
    News & Views
    Nature Reviews Nephrology
    Volume: 9, P: 197-198

  • Statins reduce the risk of atherosclerotic vascular disease in healthy individuals and those with chronic kidney disease (CKD); however, clinical trials have suggested a minimal effect of statins on CKD progression. The PLANET trials compared the renal effects of rosuvastatin and atorvastatin, but the findings leave many questions unanswered.

    • Richard Haynes
    • Christoph Wanner
    News & Views
    Nature Reviews Nephrology
    Volume: 11, P: 262-263

  • Recent analyses from the FIELD randomized trial of fenofibrate in type 2 diabetes mellitus suggests that fibrates have beneficial effects and are safe in patients with moderate renal impairment. However, too few participants with chronic kidney disease were included in the study to provide reliable information.

    • David Lewis
    • Christoph Wanner
    News & Views
    Nature Reviews Nephrology
    Volume: 8, P: 201-202

  • In this Review, participants in the 7thInternational Fabry Nephropathy Roundtable, which was convened in Barcelona, Spain in June 2007, propose guidelines and recommendations for the diagnosis and management of Fabry nephropathy in adults. The roles of enzyme replacement and antiproteinuric therapy are emphasized. The authors suggest that these organ-specific recommendations could have a greater impact on clinical practice than general Fabry disease guidelines.

    • Alberto Ortiz
    • João P Oliveira
    • David G Warnock
    Reviews
    Nature Clinical Practice Nephrology
    Volume: 4, P: 327-336

  • Inflammation is highly prevalent in patients with chronic kidney disease (CKD) and is associated with increased mortality and cardiovascular events. Besides reducing lipid levels, statins have anti-inflammatory effects that are modified by the presence of inflammation, making these agents especially effective in patients with CKD who show evidence of inflammation and raised levels of C-reactive protein. In this Review, Krane and Wanner provide an overview of statin studies in patients with CKD, and discuss how the results could influence clinical decision making.

    • Vera Krane
    • Christoph Wanner
    Reviews
    Nature Reviews Nephrology
    Volume: 7, P: 385-397